Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claim substantiation burden

This article was originally published in The Tan Sheet

Executive Summary

FDA estimates it will take 44 hours - not one hour as the agency previously estimated - for a firm to gather substantiation for a dietary supplement claim for which there is "adequate publicly available and widely established evidence supporting the claim," a June 7 Federal Register notice says. FDA increased the estimate after it received several comments challenging the original. Assembling supporting scientific information "when the claim is novel or when the claim is pre-existing but the scientific underpinnings of the claims are not widely established" is estimated to take around 120 hours per claim, FDA says. The agency disagreed with one comment challenging FDA's determination that there are no capital, operating or maintenance costs associated with the collection of the substantiation. Comments are due by July 9...

You may also be interested in...

US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques

The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.

Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease

Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.

Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts